Fastest Growing Stocks
TGTX is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
TG THERAPEUTICS INC (TGTX) Stock Price & Overview
NASDAQ:TGTX • US88322Q1085
Current stock price
33.53 USD
-0.05 (-0.15%)
At close:
33 USD
-0.53 (-1.58%)
After Hours:
The current stock price of TGTX is 33.53 USD. Today TGTX is down by -0.15%. In the past month the price increased by 15.5%. In the past year, price decreased by -10.23%.
TGTX Key Statistics
52-Week Range25.28 - 46.48
Current TGTX stock price positioned within its 52-week range.
1-Month Range26.76 - 34.33
Current TGTX stock price positioned within its 1-month range.
- Market Cap
- 5.354B
- P/E
- 67.06
- Fwd P/E
- 20.85
- EPS (TTM)
- 0.50
- Dividend Yield
- N/A
TGTX Stock Performance
Today
-0.15%
1 Week
+4.85%
1 Month
+15.50%
3 Months
+14.52%
Longer-term
6 Months -8.65%
1 Year -10.23%
2 Years +145.46%
3 Years +35.04%
5 Years -25.01%
10 Years +268.06%
TGTX Stock Chart
TGTX Stock Screens
TGTX currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
TGTX is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
TGTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TGTX. When comparing the yearly performance of all stocks, TGTX turns out to be only a medium performer in the overall market: it outperformed 43.98% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TGTX. TGTX has an average financial health and profitability rating.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TGTX Earnings
On February 26, 2026 TGTX reported an EPS of 0.14 and a revenue of 192.57M. The company missed EPS expectations (-60.92% surprise) and missed revenue expectations (-1.78% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$0.14
Revenue Reported192.574M
EPS Surprise -60.92%
Revenue Surprise -1.78%
TGTX Forecast & Estimates
15 analysts have analysed TGTX and the average price target is 45.05 USD. This implies a price increase of 34.36% is expected in the next year compared to the current price of 33.53.
For the next year, analysts expect an EPS growth of 221.55% and a revenue growth 46.45% for TGTX
Analysts
Analysts78.67
Price Target45.05 (34.36%)
EPS Next Y221.55%
Revenue Next Year46.45%
TGTX Groups
Sector & Classification
TGTX Financial Highlights
Over the last trailing twelve months TGTX reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS increased by 257.14% compared to the year before.
Income Statements
Revenue(TTM)616.29M
Net Income(TTM)447.18M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 72.56% | ||
| ROA | 42.06% | ||
| ROE | 69.01% | ||
| Debt/Equity | 0.38 |
Chartmill High Growth Momentum
EPS Q2Q%-6.67%
Sales Q2Q%78%
EPS 1Y (TTM)257.14%
Revenue 1Y (TTM)87.32%
TGTX Ownership
Ownership
Inst Owners66.06%
Shares159.69M
Float148.25M
Ins Owners7.21%
Short Float %18.99%
Short Ratio15.04
TGTX Latest News, Press Relases and Analysis
20 days ago - By: Chartmill
TGTX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TGTX
Company Profile
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 399 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Company Info
IPO: 1995-12-14
TG THERAPEUTICS INC
3020 Carrington Mill Blvd., Suite 475
Morrisville NORTH CAROLINA 10014 US
CEO: Michael S. Weiss
Employees: 399
Phone: 18775758489
TG THERAPEUTICS INC / TGTX FAQ
What does TGTX do?
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 399 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
What is the current price of TGTX stock?
The current stock price of TGTX is 33.53 USD. The price decreased by -0.15% in the last trading session.
Does TGTX stock pay dividends?
TGTX does not pay a dividend.
What is the ChartMill rating of TG THERAPEUTICS INC stock?
TGTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the Price/Earnings (PE) ratio of TG THERAPEUTICS INC (TGTX)?
The PE ratio for TG THERAPEUTICS INC (TGTX) is 67.06. This is based on the reported non-GAAP earnings per share of 0.5 and the current share price of 33.53 USD.
What is the market capitalization of TGTX stock?
TG THERAPEUTICS INC (TGTX) has a market capitalization of 5.35B USD. This makes TGTX a Mid Cap stock.
Can you provide the ownership details for TGTX stock?
You can find the ownership structure of TG THERAPEUTICS INC (TGTX) on the Ownership tab.